Estimands-A Basic Element for Clinical Trials.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
27 12 2021
27 12 2021
Historique:
received:
18
06
2021
revised:
18
06
2021
accepted:
03
11
2021
pubmed:
4
12
2021
medline:
20
4
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Clinical trials are of central importance for the evaluation and comparison of treatments. The transparency and intelligibility of the treatment effect under investigation is an essential matter for physicians, patients, and health-care authorities. The estimand framework has been introduced because many trials are deficient in this respect. Introduction, definition, and application of the estimand framework on the basis of an example and a selective review of the literature. The estimand framework provides a systematic approach to the definition of the treatment effect under investigation in a clinical trial. An estimand consists of five attributes: treatment, population, variable, population-level summary, and handling of intercurrent events. Each of these attributes is defined in an interdisciplinary discussion during the trial planning phase, based on the clinical question being asked. Special attention is given to the handling of intercurrent events (ICEs): these are events-e.g., discontinuation or modification of treatment or the use of emergency medication-that can occur once the treatment has begun and might affect the possibility of observing the endpoints or their interpretability. There are various strategies for the handling of ICEs; these can, for example, also reflect the existing intention-to-treat (ITT) principle. Per-protocol analyses, in contrast, are prone to bias and cannot be represented in a sensible manner by an estimand, although they may be performed as a supplementary analysis. The discussion of potential intercurrent events and how they should appropriately be handled in view of the aim of the trial must already take place in the planning phase. Use of the estimand framework should make it easier for both physicians and patients to understand what trials reveal about the efficacy of treatment, and to compare the results of different trials.
Sections du résumé
BACKGROUND
Clinical trials are of central importance for the evaluation and comparison of treatments. The transparency and intelligibility of the treatment effect under investigation is an essential matter for physicians, patients, and health-care authorities. The estimand framework has been introduced because many trials are deficient in this respect.
METHODS
Introduction, definition, and application of the estimand framework on the basis of an example and a selective review of the literature.
RESULTS
The estimand framework provides a systematic approach to the definition of the treatment effect under investigation in a clinical trial. An estimand consists of five attributes: treatment, population, variable, population-level summary, and handling of intercurrent events. Each of these attributes is defined in an interdisciplinary discussion during the trial planning phase, based on the clinical question being asked. Special attention is given to the handling of intercurrent events (ICEs): these are events-e.g., discontinuation or modification of treatment or the use of emergency medication-that can occur once the treatment has begun and might affect the possibility of observing the endpoints or their interpretability. There are various strategies for the handling of ICEs; these can, for example, also reflect the existing intention-to-treat (ITT) principle. Per-protocol analyses, in contrast, are prone to bias and cannot be represented in a sensible manner by an estimand, although they may be performed as a supplementary analysis. The discussion of potential intercurrent events and how they should appropriately be handled in view of the aim of the trial must already take place in the planning phase.
CONCLUSION
Use of the estimand framework should make it easier for both physicians and patients to understand what trials reveal about the efficacy of treatment, and to compare the results of different trials.
Identifiants
pubmed: 34857075
pii: arztebl.m2021.0373
doi: 10.3238/arztebl.m2021.0373
pmc: PMC8962508
doi:
pii:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-888Références
Stat Med. 2021 Apr;40(9):2257-2271
pubmed: 33567475
PLoS Med. 2005 Aug;2(8):e124
pubmed: 16060722
Diabetes Care. 2010 Oct;33(10):2217-24
pubmed: 20566676
Perspect Clin Res. 2016 Jul-Sep;7(3):144-6
pubmed: 27453832
Int J Obes (Lond). 2021 May;45(5):923-933
pubmed: 33462358
Pharm Stat. 2020 Sep;19(5):626-635
pubmed: 32198954
Pharm Stat. 2017 Jan;16(1):12-19
pubmed: 27910217
Dtsch Arztebl Int. 2011 Sep;108(39):663-8
pubmed: 22013494
BMJ. 2020 Jun 17;369:m115
pubmed: 32554564
Diabetes Care. 2019 Sep;42(9):1724-1732
pubmed: 31186300
Alzheimers Dement. 2020 May;16(5):797-803
pubmed: 32270600
Stat Med. 2017 Jan 15;36(1):5-19
pubmed: 27435045
Pharm Stat. 2021 Jul;20(4):737-751
pubmed: 33624407
Ther Innov Regul Sci. 2021 Jul;55(4):779-785
pubmed: 33821445
NPJ Digit Med. 2019 Jan 29;2:2
pubmed: 31304352
Lancet Oncol. 2020 Oct;21(10):e488-e494
pubmed: 33002444
BMC Med. 2018 Feb 21;16(1):26
pubmed: 29463308
Diabetes Obes Metab. 2019 Oct;21(10):2203-2210
pubmed: 31168921
Pharm Stat. 2015 Nov-Dec;14(6):433-47
pubmed: 26337856
Pharm Stat. 2020 Jul;19(4):370-387
pubmed: 31919979
Trials. 2021 Oct 9;22(1):686
pubmed: 34627347
Contemp Clin Trials. 2021 Sep;108:106494
pubmed: 34186242
N Engl J Med. 2021 Mar 18;384(11):989
pubmed: 33567185